Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1

Conditions

Vascular Calcification 1Neoplasm Metastasis 1Kidney Diseases 1Hyperparathyroidism 1Chronic Kidney Disease-Mineral and Bone Disorder 1Bone Diseases 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2384Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1831Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1016Vincristine 964Cetuximab 945Trastuzumab 944Prednisone 941Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
etelcalcetide hydrochloride × Clear all
NCT03960437 2023-09-21

Parsabiv-MBD

Columbia University

Phase 2 Completed
22 enrolled 14 charts
GenitourinaryHead & Neck

Bone Diseases, Hyperparathyroidism, Kidney Diseases, Neoplasm Metastasis, Chronic Kidney Disease-Mineral and Bone Disorder, Vascular Calcification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡